Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1863-1869
Journal	Annals of the rheumatic diseases
Volume	68
Issue number	12
DOIs	https://doi.org/10.1136/ard.2008.102103
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{7201a9addc3446c09361234185ea92d2,

title = "Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases",

author = "G.R. Burmester and P. Mease and B.A.C. Dijkmans and Gordon, \{K. D.\} and D. Lovell and R. Panaccione and J.G. Perez and A.L. Pangan",

year = "2009",

doi = "10.1136/ard.2008.102103",

language = "Undefined/Unknown",

volume = "68",

pages = "1863--1869",

journal = "Annals of the rheumatic diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "12",

}

TY - JOUR

T1 - Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

AU - Burmester, G.R.

AU - Mease, P.

AU - Dijkmans, B.A.C.

AU - Gordon, K. D.

AU - Lovell, D.

AU - Panaccione, R.

AU - Perez, J.G.

AU - Pangan, A.L.

PY - 2009

Y1 - 2009

U2 - 10.1136/ard.2008.102103

DO - 10.1136/ard.2008.102103

M3 - Article

C2 - 19147611

SN - 0003-4967

VL - 68

SP - 1863

EP - 1869

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

IS - 12

ER -